According to a recent LinkedIn post from Neuromod Devices Ltd, the company’s Lenire tinnitus treatment is now available in the Netherlands through HearConsult clinics in Utrecht and Mijdrecht. The post notes that tinnitus affects more than 2 million Dutch adults and cites reports of a 33% increase in incidence between 2012 and 2021.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that this move forms part of a broader strategy to expand Lenire’s footprint across Europe in response to growing demand for clinically validated tinnitus therapies. For investors, this expansion suggests incremental revenue potential in a sizable and under-served market, while also reinforcing Neuromod’s effort to build geographic diversification and clinical credibility ahead of possible further European or global rollouts.
As shared in the post, a quote from HearConsult’s owner, Koen Vernooij, indicates rising tinnitus-related demand in Dutch audiology practices and enthusiasm for offering Lenire based on evidence from European and U.S. clinics. If sustained clinician adoption follows, Neuromod could strengthen its competitive position in the tinnitus-treatment segment and support long-term valuation through recurring device and follow-up service revenues.